The researchers suggest certain refinements to the 2022 European LeukemiaNet classification ... 80%. Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

Researchers sought to determine whether DNA methylation markers could be helpful in risk stratification for patients with AML and normal cytogenetics.

Acute myeloid leukemia is one of the deadliest cancers. Leukemic stem cells responsible for the disease are highly resistant to treatment. A new editorial paper was published in Oncotarget's ...

Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The FDA has granted fast track designation to HC-7366 for the treatment of adult patients with relapsed/refractory acute ...

Treatment with Scemblix was shown to improve response rates in patients with newly diagnosed Philadelphia chromosome-positive ...

"We are incredibly grateful to the esteemed AML thought leaders who took time out of their busy schedules to share their valuable insight at our recent event. Their continued enthusiasm and ...

"We are incredibly grateful to the esteemed AML thought leaders who took time out of their busy schedules to share their valuable insight at our recent event ... treatment of relapsed or refractory ...